Detail

Keywords

Hereditary Breast and Ovarian Cancer Syndrome; Molecular Epidemiology

Research group(s)

• Hereditary Cancer Risk & Outcomes
  Head: Yen Y. Tan
  Members:
  Yen Y. Tan

Research interests

• Hereditary breast and ovarian cancer across the life course
• Personalized cancer risk prediction, early detection and prevention
• Impact of hormonal, lifestyle and surgical interventions on cancer risk and survivorship
• Disease progression, metastatic patterns, and long-term outcomes
• Patient-reported outcomes, psychosocial aspects and family impact

Techniques, methods & infrastructure

• Clinical epidemiological study designs
• Longitudinal, multivariable statistical modelling and time-to-event analysis
• Outcomes research, including psychosocial and quality of life measures
• ATHENA biobank and registry as longitudinal research infrastructure, with expansion toward a nationwide Austrian hereditary cancer consortium (AHCC)
• National and international collaborative networks (CIMBA, ENIGMA, BCAC, IBCCS, MERGE, Confluence, DK-HBOC), including translational leadership of data-driven AI-enabled decision support projects in close collaboration with computational and AI experts (PREDICTOME)

Grants

• HER-CARE: Hereditary and early onset breast cancer (2024)
  Source of Funding: EU, MSCA-Doctoral Network
  Principal Investigator
• ATHENA: Austrian hereditary breast and ovarian cancer registry (2023)
  Source of Funding: Pfizer, Research Grant
  Principal Investigator
• IBCCS: The international BRCA1/2 carrier cohort study - prospective cohort analyses (2023)
  Source of Funding: Basser Center for BRCA, Basser External Grant Program
  Principal Investigator
• BRCA-Brain: Identification and molecular analyses of brain metastasis in breast cancer patients (2022)
  Source of Funding: Medical University of Vienna, CCC Initiative Krebsforschung Research Grant
  Principal Investigator
• PREDICTOME: Precision medicine for breast cancer - multi-omics towards predicting complete remission and avoiding surgery (2021)
  Source of Funding: WWTF (Vienna Science and Technology Fund), Life Sciences Call 2020 - Precision Medicine
  Principal Investigator
• BRCA-P: Prospectively randomized place-controlled phase 3 study to determine the effect of denosumab on breast cancer prevention in BRCA1 mutation carriers (2019)
  Source of Funding: U.S. Department of Defense, Breast Cancer Research Program Breakthrough Award - Funding Level 4
  Coordinator of the collaborative project

Selected publications

1. Reichl et al. Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. Journal of Personalized Medicine. 2021; 11(9):917. Available at: https://doi.org/10.3390/jpm11090917.
2. Silvestri et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [published correction appears in JAMA Oncol. 2020 Nov 1;6(11):1815]. JAMA Oncol. 2020;6(8):1218-1230. Available at: https://doi.org/10.1001/jamaoncol.2020.2134.
3. Kuchenbaecker et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. Available at: http://dx.doi.org/10.1001/jama.2017.7112.
4. Buchanan et al. Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. J Clin Oncol. 2014;32(2):90-100. Available at: http://dx.doi.org/10.1200/JCO.2013.51.2129.
5. Tan et al. Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 132(12), pp.2876–2883. Available at: http://dx.doi.org/10.1002/ijc.27978.